Evidence map›Paper›PMID 15123585›Full record

ArticleGenome research2004

A versatile assay for high-throughput gene expression profiling on universal array matrices.

Jian-Bing Fan, Joanne M Yeakley, Marina Bibikova, Eugene Chudin, Eliza Wickham, Jing Chen, Dennis Doucet, Philippe Rigault, Baohong Zhang, Richard Shen and 6 more

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Genome research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00868192 (Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma), which is not on this map. Cited by 94 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00868192 phase2completednot on this mapstarted 2008, after this paper: background citation

Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma

TypeinterventionalSponsorWashington University School of MedicineRan2008 to 2012Enrolled38ConditionsOvarian Carcinoma, Primary Peritoneal CarcinomaArmsPemetrexed, Bevacizumab
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 1 synthesis or guideline pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
    Trial
  4. Microarrays and the Dawn of Omics Data Analysis.Advances in experimental medicine and biology · 2026
    Review
  5. Article
  6. Article
  7. Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15.Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  8. Article
  9. Vigorous Physical Activity Is Associated with Lower Risk of Metastatic-Lethal Progression in Prostate Cancer and Hypomethylation in theCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jian-Bing FanIllumina, Inc., San Diego, California 92121, USA. jfan@illumina.com
Joanne M Yeakley
Marina Bibikova
Eugene Chudin
Eliza Wickham
Jing Chen
Dennis Doucet
Philippe Rigault
Baohong Zhang
Richard Shen
Celeste McBride
Hai-Ri Li
Xiang-Dong Fu
Arnold Oliphant
David L Barker
Mark S Chee
Illumina (United States) · USUniversity of California San Diego · US

Funding

CANCER CLASSIFICATION BASED ON MRNA ISOFORMSR33CA088351 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI FU, XIANG-DONG · 2001 to 2003
$2.6M
Parallel Array ProcessorR44CA083398 · NCI · ILLUMINA, INC. · PI CHEE, MARK S. · 2002 to 2003
$1.0M
NCI NIH HHS R33 CA088351NCI NIH HHS R33 CA88351NCI NIH HHS R44 CA83398
6 · The paper itself

Abstract

We report a flexible, sensitive, and quantitative gene-expression profiling system for assaying more than 400 genes, with three probes per gene, for 96 samples in parallel. The cDNA-mediated annealing, selection, extension and ligation (DASL) assay targets specific transcripts, using oligonucleotides containing unique address sequences that can hybridize to universal arrays. Cell-specific gene expression profiles were obtained using this assay for hormone-treated cell lines and laser-capture microdissected cancer tissues. Gene expression profiles derived from this assay were consistent with those determined by qRT-PCR. The DASL assay has been automated for use with a bead-based 96-array matrix system. The combined high-throughput assay and readout system is accurate and efficient, and can cost-effectively profile the expression of hundreds of genes in thousands of samples.

Indexed as

AndrogensAnimalsCell LineCell Line, TumorDNA, ComplementaryGene Expression ProfilingGene Expression RegulationHumansLasersMaleMiceMicrodissectionOligonucleotide Array Sequence AnalysisOrgan SpecificityProstatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionAndrogensDNA, ComplementaryRNA

Identifiers

PMID15123585
PMCPMC479115
OpenAlexW2165246391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.